AF-710B
- Generic Name
- AF-710B
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N3OS
- CAS Number
- 1235733-73-9
- Unique Ingredient Identifier
- AAE07Z061B
A Study of ANAVEX3-71 in Adults With Schizophrenia
Phase 2
Active, not recruiting
- Conditions
- Schizophrenia
- Interventions
- Drug: Placebo oral capsules
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 71
- Registration Number
- NCT06245213
- Locations
- 🇺🇸
CenExel Hassman Research Institute, Marlton, New Jersey, United States
Phase 1 Study of ANAVEX3-71
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 36
- Registration Number
- NCT04442945
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath